EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs . Sunitinib) for Advanced Renal Cell Carcinoma

Motohiro Fujiwara, Soichiro Yoshida, Shugo Yajima, Hiroyuki Sato, Akihiro Hirakawa, Hiroshi Fukushima, Yuki Arita, Hajime Tanaka, Minato Yokoyama, Hitoshi Masuda, Yasuhisa Fujii

Anticancer Research · 2026-07 · 46 (7) · 3889-3896

DOI: 10.21873/anticanres.18250 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Motohiro Fujiwara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Teikyo University Hospital, Mizonokuchi, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsPhenylurea CompoundsQuinolinesSunitinibFemaleHumansMaleBayes TheoremEast Asian PeopleProgression-Free Survival

Stichwörter der Autor:innen

Bayesian borrowingEast AsiaRenal cell carcinomalenvatinibpembrolizumabsunitinib

Substanzen

Antibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolinesSunitinib

Autor:innen und Institutionen

  • Department of Urology, Teikyo University Hospital, Mizonokuchi, Japan.
  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan; s-yoshida.uro@tmd.ac.jp.
  • Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.

Zitieren

APA

Fujiwara, M., Yoshida, S., Yajima, S., Sato, H., Hirakawa, A., Fukushima, H., Arita, Y., Tanaka, H., Yokoyama, M., Masuda, H., & Fujii, Y. (2026). Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs . Sunitinib) for Advanced Renal Cell Carcinoma. Anticancer Research, 46(7), 3889-3896. https://doi.org/10.21873/anticanres.18250

Vancouver

Fujiwara M, Yoshida S, Yajima S, Sato H, Hirakawa A, Fukushima H, et al. Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs . Sunitinib) for Advanced Renal Cell Carcinoma. Anticancer Research. 2026;46(7):3889-3896. doi:10.21873/anticanres.18250

BibTeX
@article{Fujiwara2026,
  author = {Fujiwara, Motohiro and Yoshida, Soichiro and Yajima, Shugo and Sato, Hiroyuki and Hirakawa, Akihiro and Fukushima, Hiroshi and Arita, Yuki and Tanaka, Hajime and Yokoyama, Minato and Masuda, Hitoshi and Fujii, Yasuhisa},
  title = {Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs . Sunitinib) for Advanced Renal Cell Carcinoma},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {7},
  pages = {3889--3896},
  doi = {10.21873/anticanres.18250}
}
Kostenlos starten →